35 related articles for article (PubMed ID: 20615193)
1.
Work HM; Kandel SE; Lampe JN
Drug Metab Dispos; 2024 May; ():. PubMed ID: 38702193
[TBL] [Abstract][Full Text] [Related]
2. A physiologically-based pharmacokinetic/pharmacodynamic modeling approach for drug-drug-gene interaction evaluation of S-warfarin with fluconazole.
Geng K; Shen C; Wang X; Wang X; Shao W; Wang W; Chen T; Sun H; Xie H
CPT Pharmacometrics Syst Pharmacol; 2024 May; 13(5):853-869. PubMed ID: 38487942
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous Characterization and Determination of Warfarin and Its Hydroxylation Metabolites in Rat Plasma by Chiral Liquid Chromatography-Tandem Mass Spectrometry.
Jin S; Li Z; Yang Q; Fang B; Xiang X; Peng C; Cai W
Pharmaceutics; 2022 May; 14(6):. PubMed ID: 35745714
[TBL] [Abstract][Full Text] [Related]
4. Discovery of Novel Reductive Elimination Pathway for 10-Hydroxywarfarin.
Pouncey DL; Barnette DA; Sinnott RW; Phillips SJ; Flynn NR; Hendrickson HP; Swamidass SJ; Miller GP
Front Pharmacol; 2021; 12():805133. PubMed ID: 35095511
[TBL] [Abstract][Full Text] [Related]
5. Influence of Shenxiong Glucose Injection on the Activities of Six CYP Isozymes and Metabolism of Warfarin in Rats Assessed Using Probe Cocktail and Pharmacokinetic Approaches.
Sun J; Lu Y; Li Y; Pan J; Liu C; Gong Z; Huang J; Zheng J; Zheng L; Li Y; Liu T; Wang Y
Molecules; 2017 Nov; 22(11):. PubMed ID: 29156621
[TBL] [Abstract][Full Text] [Related]
6. Stereospecific Metabolism of
Barnette DA; Johnson BP; Pouncey DL; Nshimiyimana R; Desrochers LP; Goodwin TE; Miller GP
Drug Metab Dispos; 2017 Sep; 45(9):1000-1007. PubMed ID: 28646078
[TBL] [Abstract][Full Text] [Related]
7. A Combined Molecular Docking/Dynamics Approach to Probe the Binding Mode of Cancer Drugs with Cytochrome P450 3A4.
Panneerselvam S; Yesudhas D; Durai P; Anwar MA; Gosu V; Choi S
Molecules; 2015 Aug; 20(8):14915-35. PubMed ID: 26287147
[TBL] [Abstract][Full Text] [Related]
8. A cellular system for quantitation of vitamin K cycle activity: structure-activity effects on vitamin K antagonism by warfarin metabolites.
Haque JA; McDonald MG; Kulman JD; Rettie AE
Blood; 2014 Jan; 123(4):582-9. PubMed ID: 24297869
[TBL] [Abstract][Full Text] [Related]
9. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7.
Williams JA; Ring BJ; Cantrell VE; Jones DR; Eckstein J; Ruterbories K; Hamman MA; Hall SD; Wrighton SA
Drug Metab Dispos; 2002 Aug; 30(8):883-91. PubMed ID: 12124305
[TBL] [Abstract][Full Text] [Related]
10. Metabolism of R- and S-warfarin by CYP2C19 into four hydroxywarfarins.
Kim SY; Kang JY; Hartman JH; Park SH; Jones DR; Yun CH; Boysen G; Miller GP
Drug Metab Lett; 2012 Sep; 6(3):157-64. PubMed ID: 23331088
[TBL] [Abstract][Full Text] [Related]
11. Variation in Expression of Cytochrome P450 3A Isoforms and Toxicological Effects: Endo- and Exogenous Substances as Regulatory Factors and Substrates.
Fujino C; Sanoh S; Katsura T
Biol Pharm Bull; 2021; 44(11):1617-1634. PubMed ID: 34719640
[TBL] [Abstract][Full Text] [Related]
12. Contribution of three CYP3A isoforms to metabolism of R- and S-warfarin.
Jones DR; Kim SY; Boysen G; Yun CH; Miller GP
Drug Metab Lett; 2010 Dec; 4(4):213-9. PubMed ID: 20615193
[TBL] [Abstract][Full Text] [Related]
13. Hydroxywarfarin metabolites potently inhibit CYP2C9 metabolism of S-warfarin.
Jones DR; Kim SY; Guderyon M; Yun CH; Moran JH; Miller GP
Chem Res Toxicol; 2010 May; 23(5):939-45. PubMed ID: 20429590
[TBL] [Abstract][Full Text] [Related]
14. Genetic contribution to variable human CYP3A-mediated metabolism.
Lamba JK; Lin YS; Schuetz EG; Thummel KE
Adv Drug Deliv Rev; 2002 Nov; 54(10):1271-94. PubMed ID: 12406645
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
